Persistence Pays Off for Tacere Execs
This article was originally published in Start Up
Executive Summary
RNAi firm Tacere's deal with Pfizer demonstrates pharmaceutical companies' interest in exploring a variety of RNA interference techniques as well as the rewards sometimes associated with the dogged development of a single project.
You may also be interested in...
Gene Therapy: The Next Big Thing?
Investors' and Big Pharmas' hitherto frosty view of gene-based medicines may be starting to thaw, at least in places, warmed by clinical progress and a smattering of deals. Is there any real potential in this market? Until the first FDA approval, no-one's expecting any real heat. But there are companies which are enjoying limited success in the early stages, whose experience most likely reflects where at least the near-term potential of gene-based medicines lie.
Tacere Inks Deal With Oncolys BioPharma For RNAi Candidate
Firm's lead candidate for hepatitis C is expected to enter Phase I in late 2008.
In RNAi, Technology Proliferates Beyond the Big Two
If 2006 was a breakout year for RNAi the concept, then 2007 could be a breakout year for RNAi drug development itself. In the past few years there has been a surge of newcomers to the space, in some cases sporting high-quality venture backers and boldfaced names in RNAi. Some companies have decided to play ball with the industry leaders, sublicensing Alnylam's IP around their chosen targets, for example; others have filed their own IP-either outside the Alnylam and Merck umbrellas or putting them on a relatively slow-motion collision course with the two power brokers; still others have argued that patenting novel delivery technologies will provide them with the necessary edge in licensing negotiations, should they come about, or with pharmaceutical partners.